TD Cowen downgraded Stoke Therapeutics from Outperform to Market Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2025 | $30.00 | Buy | Jefferies |
| 12/20/2024 | $24.00 | Buy | Chardan Capital Markets |
| 10/14/2024 | $18.00 | Outperform | Leerink Partners |
| 3/26/2024 | Market Perform → Outperform | TD Cowen | |
| 11/20/2023 | Neutral | JP Morgan | |
| 7/25/2023 | Outperform → Market Perform | TD Cowen | |
| 5/1/2023 | $9.00 → $12.00 | Underperform → Neutral | BofA Securities |
| 4/26/2023 | $24.00 | Buy | Canaccord Genuity |
Jefferies initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $30.00
Chardan Capital Markets initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00
Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00
144 - Stoke Therapeutics, Inc. (0001623526) (Subject)
144 - Stoke Therapeutics, Inc. (0001623526) (Subject)
SCHEDULE 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and consistent with the ongoing Phase 3 EMPEROR study— —Analysis of electroencephalogram (EEG) supports a disease-modifying mechanism of action— Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and consistent with the ongoing Phase 3 EMPEROR study— —Analysis of electroencephalogram (EEG) supports a disease-modifying mechanism of action— CAMBRIDGE, Mass. and BEDFORD, Mass., Dec. 05, 2025 (GLO
CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia. Zorevunersen is an investigational antisense oligonucleotide currently being evaluated as a potential first-in-class medicine for the treatment of Dravet syndrome, a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures and sign
SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
– Global Phase 3 EMPEROR study patient recruitment ongoing in the U.S., UK, and Japan with more than 20 patients randomized to zorevunersen or sham; Study on track to complete enrollment in second half of 2026 – – As of September 30, 2025, the Company had $328.6 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 – – Webcast and conference call for analysts and investors at 4:30PM Eastern Time today – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a fi
Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, November 4, 2025, at 4:30 p.m. ET, to discuss third quarter 2025 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the cal
– First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome – – New 3-year zorevunersen OLE data provide additional support for disease modification: continuing and durable reductions in seizures and improvements in cognition and behavior and generally well tolerated – – Phase 1 study of STK-002 initiated in patients with Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder – – As of June 30, 2025, the Company had $355.0 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 and into launch readiness – – Webcast and conference call for analysts and investors a
– Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou
– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div